Shares of Sysmex Corporation ADR (OTCMKTS:SSMXY - Get Free Report) gapped down before the market opened on Wednesday . The stock had previously closed at $8.50, but opened at $8.16. Sysmex shares last traded at $8.53, with a volume of 1,667 shares traded.
Wall Street Analyst Weigh In
Separately, Citigroup downgraded Sysmex from a "strong-buy" rating to a "hold" rating in a report on Monday, March 16th. One analyst has rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold".
Get Our Latest Stock Analysis on SSMXY
Sysmex Stock Performance
The stock has a market capitalization of $5.36 billion, a PE ratio of 17.72 and a beta of 1.14. The company has a quick ratio of 2.44, a current ratio of 3.33 and a debt-to-equity ratio of 0.12. The firm has a 50 day moving average price of $9.20 and a 200-day moving average price of $10.31.
Sysmex (OTCMKTS:SSMXY - Get Free Report) last announced its quarterly earnings data on Thursday, February 12th. The company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.14 by $0.01. The business had revenue of $837.32 million during the quarter, compared to analysts' expectations of $819.99 million. Sysmex had a net margin of 8.86% and a return on equity of 9.27%. Research analysts expect that Sysmex Corporation ADR will post 0.57 EPS for the current fiscal year.
About Sysmex
(
Get Free Report)
Sysmex Corporation OTCMKTS: SSMXY is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex's product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.
The company's core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sysmex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sysmex wasn't on the list.
While Sysmex currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
